Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

With high regard for China's vast market potential and dynamic innovation ecosystem, Opella, Sanofi's consumer healthcare ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

To sweeten the Opella deal, the issuer made concessions ... commitment to CD&R last year so the firm could buy part of Sanofi’s consumer arm. But they had to keep the debt on their balance ...

The debt package for the unit, which is called Opella, was one of the most hotly anticipated financing deals to come to market this year in Europe and the US. It included €5.2 billion-equivalent ...

sale of leveraged loans and high-yield bonds to finance Clayton Dubilier & Rice ’s purchase of a stake in Sanofi SA ’s consumer health division. The debt package for the unit, which is called Opella, ...

The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY).Designed for patients aged 12 and older ...

Into this crowded treatment landscape comes another new medicine as the FDA has signed off on Sanofi’s Qfitlia (fitusiran), which sets itself apart as the only treatment for all types of hemophilia.

Investing.com -- The US Food and Drug Administration (FDA) has approved Sanofi (NASDAQ:SNY)’s treatment for hemophilia, Qfitlia (fitusiran), which can be administered as infrequently as once ...

The key reason I highlight is the ongoing process of spinning off its consumer healthcare unit, which is called Opella. So, on the Q4 earnings call, Francois Roger, Sanofi's CFO, made the ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Merck KGaA, Pfizer and Sanofi were among more than 40 international business leaders who met with Xi in ...